Comparison of Different Treatment Regimens for Long-term Improvement
of Renal Function in Patients with Henoch-Schönlein Purpura: A
Systematic Review

Razieh      Reicy; Mohsen      Jari

doi:10.2174/1573397119666230825163008

Abstract

Backgrounds: Henoch-Schönlein purpura (IgA vasculitis) is the most common childhood vasculitis, one of its complications is renal involvement. However, several treatment regimens have been proposed to improve renal function in the long term, but which drug regimen can be most effective is still controversial.

Methods: This study was a systematic review. In order to find evidence related to the purpose of this study, databases including Google Scholar, Web of Science, ProQuest and Medline via PubMed, and Scopus were searched with the appropriate keywords. QUADAS-2 (a Quality Assessment tools for Diagnostic Accuracy Studies) checklist was also used to evaluate the quality of studies. Based on the keywords used in reviewing the information sources of scientific articles, in the first stage, 86 studies were included in the review. Taking into account characteristics such as lack of homogeneity with the objectives of the present study, finally, 11 studies were selected for analysis and final evaluation.

Results: A total of 11 studies, including 722 patients in the age range of 5.5 to 9.9 years with HSP were included in the study. The follow-up period of the patients varied from 6 months to 16 years in terms of examining the treatment process. In terms of study type, 7 studies were conducted as prospective or retrospective (non-interventional) cohorts and 4 studies as randomized clinical trials. The treatment regimen of injectable methylprednisolone followed by oral prednisolone resulted in a long-term recovery of 79.2% (95% confidence interval between 0.66% and 88.2%); however, the need for additional immunosuppressive in two studies was mentioned as 38% and 46.1%, respectively. In the therapeutic regimen of oral methylprednisolone alone, a significant improvement in long-term renal function was achieved in comparison with placebo. Administration of injectable methylprednisolone followed by cyclosporine A had the highest effectiveness in terms of improving renal function in the long term.

Conclusion: Regimes based on the administration of prednisolone (either oral or injectable, either as a single drug or as a combination) lead to long-term improvement of renal function in patients with HSP, but the use of other immunosuppressive drugs such as cyclosporine A, of course, with optimizing the drug dose can lead to a significant improvement in the clinical performance.

Keywords: Henoch-Schönlein purpura, Ig A vasculitis, nephritis, renal function, drug regimen, long-term improvement.

« Previous Next »

Graphical Abstract

[1]
Jauhola O, Ronkainen J, Autio-Harmainen H, et al. Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: A randomized trial. Pediatr Nephrol  2011; 26(12): 2159-66.
 [http://dx.doi.org/10.1007/s00467-011-1919-5] [PMID: 21626222]

[2]
Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: A randomized, double-blind, placebo-controlled trial. J Pediatr  2006; 149(2): 241-7.
 [http://dx.doi.org/10.1016/j.jpeds.2006.03.024] [PMID: 16887443]

[3]
Hahn D, Hodson EM, Willis NS, Craig JC. Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). Cochrane Libr  2015; 2015(8): CD005128.
 [http://dx.doi.org/10.1002/14651858.CD005128.pub3] [PMID: 26258874]

[4]
Du Y, Hou L, Zhao C, Han M, Wu Y. Treatment of children with Henoch-Schönlein purpura nephritis with mycophenolate mofetil. Pediatr Nephrol  2012; 27(5): 765-71.
 [http://dx.doi.org/10.1007/s00467-011-2057-9] [PMID: 22081165]

[5]
Xiong J-C, Tian M. Efficacy and safety of mycophenolate mofetil for Henoch-Schonlein purpura nephritis: A systematic review. Chin J Evidence-Based Med  2014; 14: 184-90.

[6]
Bech AP, Reichert LJ, Cohen Tervaert JW. Dapsone for the treatment of chronic IgA vasculitis (Henoch-Schonlein). Neth J Med  2013; 71(4): 220-1.
 [PMID: 23723120]

[7]
Mazille N, Lipsker D, Fischbach M. Dapsone treatment of chronic cutaneous forms of rheumatoid purpura: About 3 cases. Arch Pediatr  2011; 18(11): 1201-4.
 [http://dx.doi.org/10.1016/j.arcped.2011.08.011] [PMID: 21963373]

[8]
Pillebout E, Rocha F, Fardet L, Rybojad M, Verine J, Glotz D. Successful outcome using rituximab as the only immunomodulation in Henoch-Schonlein purpura: Case report. Nephrol Dial Transplant  2011; 26(6): 2044-6.
 [http://dx.doi.org/10.1093/ndt/gfr137] [PMID: 21436378]

[9]
Bellan M, Pirisi M, Sainaghi PP. Long-term remission of corticosteroid- and cyclophosphamide-resistant HenochSchonlein purpura with rituximab. Scand J Rheumatol  2015; 27.
 [PMID: 26312648]

[10]
Pindi ST, Michot JM, Snanoudj R, et al. Successful outcome of a corticodependent henoch-schönlein purpura adult with rituximab. Case Rep Med  2014; 2014: 1-4.
 [http://dx.doi.org/10.1155/2014/619218] [PMID: 24799911]

[11]
Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E. the CESAR study group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int  2010; 78(5): 495-502.
 [http://dx.doi.org/10.1038/ki.2010.150] [PMID: 20505654]

[12]
Kawasaki Y, Ono A, Ohara S, et al. Henoch-Schonlein purpura nephritis in childhood: Pathogenesis, prognostic factors and treatment. Fukushima J Med Sci  2013; 59(1): 15-26.
 [http://dx.doi.org/10.5387/fms.59.15] [PMID: 23842510]

[13]
Yan M, Wang Z, Niu N, Zhao J, Peng J. Relationship between chronic tonsillitis and Henoch-Schonlein purpura. Int J Clin Exp Med  2015; 8(8): 14060-4.
 [PMID: 26550368]

[14]
Barut K, Sahin S, Kasapcopur O. Pediatric vasculitis. Curr Opin Rheumatol  2016; 28(1): 29-38.
 [http://dx.doi.org/10.1097/BOR.0000000000000236] [PMID: 26555448]

[15]
Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ  2021; 372(160): n160.
 [http://dx.doi.org/10.1136/bmj.n160] [PMID: 33781993]

[16]
Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: A systematic review. J Evid Based Med  2015; 8(1): 2-10.
 [http://dx.doi.org/10.1111/jebm.12141] [PMID: 25594108]

[17]
Shin JI, Lee SJ, Lee JS, Kim KH. Intravenous dexamethasone followed by oral prednisolone versus oral prednisolone in the treatment of childhood Henoch-Schönlein purpura. Rheumatol Int  2011; 31(11): 1429-32.
 [http://dx.doi.org/10.1007/s00296-010-1507-1] [PMID: 20464400]

[18]
Koskela M, Jahnukainen T, Endén K, et al. Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: A nationwide study. Pediatr Nephrol  2019; 34(8): 1447-56.
 [http://dx.doi.org/10.1007/s00467-019-04238-2] [PMID: 30955086]

[19]
Huber AM, King J, McLaine P, Klassen T, Pothos M. A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura. BMC Med  2004; 2: 2-7.
 [http://dx.doi.org/10.1186/1741-7015-2-7]

[20]
Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB. Treatment of Henoch-Schönlein Purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol  2001; 21(2): 128-33.
 [http://dx.doi.org/10.1159/000046235] [PMID: 11359020]

[21]
Niaudet P, Habib R. Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol  1998; 12(3): 238-43.
 [http://dx.doi.org/10.1007/s004670050446] [PMID: 9630046]

[22]
Mollica F, LiVolti S, Garozzo R, Russo G. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr  1992; 151(2): 140-4.
 [http://dx.doi.org/10.1007/BF01958961] [PMID: 1343079]

[23]
Hisano S, Hatae K, Yamane I, Uragoh K, Ueda K. High-dose methylprednisolone therapy for nephrotic syndrome in Henoch-Schoenlein nephritis. Nippon Jinzo Gakkai Shi  1989; 31(10): 1055-60.
 [PMID: 2615017]

[24]
Buchanec J, Galanda V, Beláková S, Minárik M, Zibolen M. The effect of prednisone in the development of nephropathy in Schoenlein-Henoch purpura. Cesk Pediatr  1989; 44(3): 145-6.
 [PMID: 2731281]

[25]
Rose GM, Cole BR, Robson AM. The treatment of severe glomerulopathies in children using high dose intravenous methylprednisolone pulses. Am J Kidney Dis  1981; 1(3): 148-56.
 [http://dx.doi.org/10.1016/S0272-6386(81)80021-2] [PMID: 7332007]

[26]
Buscatti IM, Casella BB, Aikawa NE, et al. Henoch-Schönlein purpura nephritis: Initial risk factors and outcomes in a Latin American tertiary center. Clin Rheumatol  2018; 37(5): 1319-24.
 [http://dx.doi.org/10.1007/s10067-017-3972-3] [PMID: 29330742]

Rights & Permissions Print Cite

Article Metrics

21

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1573397119666230825163008	Print ISSN 1573-3971
Publisher Name Bentham Science Publisher	Online ISSN 1875-6360

Current Rheumatology Reviews

Comparison of Different Treatment Regimens for Long-term Improvement of Renal Function in Patients with Henoch-Schönlein Purpura: A Systematic Review

Abstract

Graphical Abstract

Related Books

Related Articles